CAM
EWTX icon

Cormorant Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Cormorant Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102M Sell
2,510,000
-750,000
-23% -$25.9M 5.23% 6
2026
Q1 		$103M Sell
3,260,000
-25,000
-0.8% -$721K 5.16% 4
2025
Q4 		$81.5M Sell
3,285,000
-725,000
-18% -$14.6M 3.77% 11
2025
Q3 		$65M Sell
4,010,000
-241,992
-6% -$3.43M 4.49% 6
2025
Q2 		$55.7M Buy
4,251,992
+150,000
+4% +$2.16M 4.15% 6
2025
Q1 		$90.2M Buy
4,101,992
+695,458
+20% +$18.2M 6.79% 2
2024
Q4 		$91M Hold
3,406,534
– – 5% 5
2024
Q3 		$90.9M Buy
3,406,534
+400,000
+13% +$7.96M 4.82% 5
2024
Q2 		$54.1M Hold
3,006,534
– – 3.13% 9
2024
Q1 		$54.8M Buy
3,006,534
+454,545
+18% +$7.22M 2.41% 10
2023
Q4 		$27.9M Sell
2,551,989
-394,898
-13% -$2.77M 1.33% 21
2023
Q3 		$16.9M Hold
2,946,887
– – 0.99% 25
2023
Q2 		$22.8M Hold
2,946,887
– – 1.28% 24
2023
Q1 		$19.7M Hold
2,946,887
– – 1.29% 21
2022
Q4 		$26.3M Sell
2,946,887
-105,102
-3% -$985K 1.76% 17
2022
Q3 		$30M Sell
3,051,989
-798,011
-21% -$8.06M 2.1% 17
2022
Q2 		$30.6M Sell
3,850,000
-832,874
-18% -$6.3M 2.32% 12
2022
Q1 		$45.4M Buy
4,682,874
+1,116,973
+31% +$14.4M 3.49% 8
2021
Q4 		$54.5M Buy
3,565,901
+194,987
+6% +$3.51M 3.24% 8
2021
Q3 		$56M Buy
3,370,914
+230,000
+7% +$4.16M 2.27% 12
2021
Q2 		$66.5M Buy
3,140,914
+800,000
+34% +$21.9M 2.26% 12
2021
Q1 		$74.3M Buy
+2,340,914
New +$75.9M 1.66% 14

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cormorant Asset Management's EWTX Position: Q2 2026 in Review

Cormorant Asset Management reduced its Edgewise Therapeutics (EWTX) stake by 23% in Q2 2026, selling an estimated $25.9M and leaving 2,510,000 shares worth $102M. The position accounts for 5.23% of the portfolio, ranked #6.

Cormorant Asset Management first reported a position in EWTX in Q1 2021 and has held it in 22 quarters since. The position peaked at $103M in Q1 2026. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Cormorant Asset Management held 2,510,000 shares of Edgewise Therapeutics worth $102M as of Q2 2026.
  • Cormorant Asset Management sold 750,000 Edgewise Therapeutics shares in Q2 2026, an estimated $25.9M.
  • Edgewise Therapeutics made up 5.23% of Cormorant Asset Management's portfolio in Q2 2026, its #6 holding.
  • Cormorant Asset Management first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Cormorant Asset Management's Edgewise Therapeutics position peaked at $103M in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.